1. Home›
  2. Hair Loss›
  3. Finasteride for Hair Loss›
  4. Finasteride Dosage: Standard Doses, Variations, and What the Evidence Shows

Curekey medical guide·7 min read

Finasteride Dosage: Standard Doses, Variations, and What the Evidence Shows

An evidence-based look at finasteride dosing for pattern hair loss, including the FDA-approved 1 mg standard, lower-dose protocols, and why dosage decisions belong to a physician.

In this article

  1. The FDA-approved standard dose
  2. Why 1 mg was chosen
  3. Lower-dose research and emerging interest
  4. Higher doses (5 mg) are not generally used for hair loss
  5. Splitting tablets and pharmacy considerations
  6. Missed doses and adherence
  7. Why dosage decisions belong with a physician
  8. Considering medical assessment
  9. Key references

Finasteride dosage seems on the surface like a settled question: the FDA-approved dose for pattern hair loss is 1 mg daily, and that has been the standard for nearly three decades. In practice, dosing has become a more nuanced topic in recent years, with growing research interest in lower doses, alternative schedules, and more individualized approaches. This page lays out what the evidence currently supports, what is being studied, and why dosing decisions, even at the level of "should I take half a tablet," belong with a physician rather than with a forum thread.

The goal here is not to recommend any particular dose. Dose selection depends on the individual, the diagnosis, the goals of treatment, and the broader medical picture. What we can usefully do is summarize what is known.

The FDA-approved standard dose

For androgenetic alopecia in men, the FDA-approved dose of finasteride is 1 mg taken orally once daily. This is the dose that was studied in the pivotal phase III trials and the dose at which the long-term safety and efficacy data were generated.

Several practical points about the 1 mg standard:

Curekey physician with oral hair-loss treatment
  • It can be taken with or without food.
  • It can be taken at any time of day, though most patients pick a consistent time to support adherence.
  • Steady-state DHT suppression is reached within roughly 1 to 2 weeks of starting daily dosing.
  • The medication has a serum half-life of approximately 6 to 8 hours, but the biological effect on the 5-alpha-reductase enzyme outlasts the serum drug.
  • Missing an occasional dose generally does not abolish DHT suppression, because of the duration of enzyme inhibition.

The 5 mg formulation of finasteride is approved for benign prostatic hyperplasia (BPH), not for hair loss. The two indications are pharmacologically related but clinically distinct, and the 1 mg dose is what was specifically studied for hair-loss outcomes.

Why 1 mg was chosen

The choice of 1 mg as the hair-loss dose was not arbitrary. Dose-finding studies showed that DHT suppression curves with finasteride flatten at relatively low doses. Specifically:

  • At 0.2 mg daily, mean serum DHT is suppressed by roughly 50 to 60 percent.
  • At 1 mg daily, suppression reaches roughly 65 to 70 percent.
  • At 5 mg daily, suppression is in the same range as 1 mg, with limited additional reduction.

This is the saturation curve: doubling the dose from 1 mg to 5 mg does not double the DHT suppression. Above 1 mg, the marginal benefit on DHT levels is small, while the systemic exposure increases. This is why 1 mg was selected as the hair-loss dose: it is at or near the upper part of the saturation curve, providing most of the achievable DHT suppression without the higher systemic dose used for BPH.

For a deeper dive on the underlying enzyme biology, our companion guide How Finasteride Treats Hair Loss covers the mechanism in detail.

Lower-dose research and emerging interest

Because the dose-response curve for DHT suppression flattens early, several research groups have asked whether lower doses than 1 mg might be effective for hair loss with potentially fewer side effects. This is an area of growing interest, and several findings are worth understanding:

  • 0.5 mg daily has been studied in smaller trials and appears to produce DHT suppression and hair-count outcomes that are broadly similar to 1 mg, though with a somewhat smaller effect size in some studies.
  • 0.2 mg daily suppresses DHT to a lesser degree but still meaningfully and has been associated with hair-count improvements in some studies.
  • Every-other-day dosing of 1 mg or 0.5 mg has been explored as a way to maintain steady-state suppression with reduced cumulative exposure, though the data is more limited.
  • Topical finasteride is a related but distinct topic. It aims to deliver the medication preferentially to the scalp with reduced systemic exposure. Several formulations have been studied, with promising but not yet definitive results.

What the research does not currently support is a clear, evidence-based recommendation that all patients should take less than 1 mg, or that lower doses fully eliminate side-effect risk. The trade-off between efficacy and tolerability at sub-1-mg doses is still being characterized, and individual response varies.

For a physician considering a lower-dose protocol for a specific patient, the relevant context includes baseline DHT levels, patient preference around side-effect risk, prior tolerability, and the clinical goals of treatment.

Talk to a licensed physician about your hair loss

Take a short online assessment. A U.S.-licensed physician will review your medical history and recommend a personalized treatment plan.

See if oral treatment is right for you

Higher doses (5 mg) are not generally used for hair loss

The 5 mg formulation of finasteride is approved for BPH and is sometimes prescribed in BPH contexts where prostate volume reduction is the goal. For hair loss, 5 mg has no demonstrated additional benefit over 1 mg on the relevant scalp outcomes, while systemic exposure is meaningfully higher.

Some patients searching for stronger DHT suppression for hair loss may consider 5 mg, but the dose-response data does not support this approach for hair loss specifically. If a patient is not seeing adequate response on 1 mg, the more evidence-based next steps are typically to assess adherence, examine whether combination therapy with minoxidil would help, and discuss whether a switch to dutasteride (a dual-isoform inhibitor with greater DHT suppression) is appropriate.

Splitting tablets and pharmacy considerations

Patients sometimes split 1 mg tablets to achieve a lower dose, or split 5 mg tablets to reach approximately 1 mg. There are practical considerations here:

  • Tablet uniformity. Commercial finasteride tablets are not always perfectly uniform when split. Splitting introduces dose variability.
  • Coatings. Some finasteride tablets have a coating that helps prevent skin contact with the active drug. Splitting compromises this coating, which has handling implications, particularly in households where pregnant individuals may handle the tablets.
  • Compounded formulations. Some specialty pharmacies offer compounded finasteride at non-standard strengths (for example, 0.25 mg or 0.5 mg tablets, or topical formulations) under physician prescription. This avoids the variability and handling issues of splitting.
  • Consistency. Whatever the chosen dose, taking it consistently is more important than the precise milligram amount within the typical effective range.

These considerations are why dose changes are best discussed with a prescribing physician, not improvised at home.

Missed doses and adherence

Because of the relatively long duration of enzyme inhibition and the saturation curve at the standard dose, missing an occasional dose of finasteride is generally not catastrophic. DHT levels do not fully rebound from a single missed day. The general guidance:

  • If you remember within several hours of your usual time, take the missed dose.
  • If you are close to the next scheduled dose, skip the missed one and resume the normal schedule. Do not double up.
  • Consistent daily dosing is the goal, but a missed dose here or there does not undo treatment.

Sustained adherence over months and years matters far more than any single missed day. The most reliable predictor of long-term response is, simply, taking the medication consistently for long enough to allow the hair growth cycle to respond.

Talk to a licensed physician about your hair loss

Take a short online assessment. A U.S.-licensed physician will review your medical history and recommend a personalized treatment plan.

See if oral treatment is right for you

Why dosage decisions belong with a physician

This is worth being explicit about. Even though the standard dose is well-established, several aspects of dosing are individualized:

  • Whether to start with 1 mg or consider a lower dose first
  • Whether to escalate, de-escalate, or switch in response to early experience
  • Whether to combine with minoxidil and what minoxidil dose
  • Whether topical or oral formulations are more appropriate for the individual
  • Whether side-effect history calls for a specific protocol
  • How to monitor response and when to adjust

These are clinical judgments that depend on the patient's medical history, preferences, current regimen, and goals. A physician can also confirm the diagnosis, address contraindications, and arrange ongoing follow-up. Dose self-adjustment without medical input introduces risk on multiple fronts: missing diagnostic context, inadvertent side-effect attribution, and inconsistent response tracking.

Considering medical assessment

If you are considering finasteride or are already on it and wondering whether your dose is right, the next step is a clinical conversation. Bring whatever data you have (consistent monthly photos, side-effect log, current adherence pattern), and a prescribing physician can help interpret your trajectory and decide whether to continue the current dose, adjust, or change strategy. The standard 1 mg dose remains the most evidence-based starting point for most men with pattern hair loss, but personalization within a clinical framework is increasingly common, and that is the right context for it. Our How Curekey Works page outlines a model of physician-led, ongoing care that supports this kind of dosing dialogue over time.

Key references

  • Kaufman KD et al. J Am Acad Dermatol, 1998. Finasteride in the treatment of men with androgenetic alopecia.
  • Andriole GL et al. NEJM, 2010. REDUCE trial: effect of dutasteride on prostate cancer risk.
  • Piraccini BM et al. J Eur Acad Dermatol Venereol, 2022. Topical finasteride efficacy and safety.

More on Finasteride for Hair Loss

  • Finasteride Shedding: When It Starts, How Long It Lasts, and What's Normal

    Hair shedding is common in the first months on finasteride. Here's why it happens, when it typically starts, how long it lasts, and how to tell normal shedding from a problem.

    Read more→
  • Finasteride Timeline: What to Expect Month by Month

    A realistic month-by-month timeline of what happens on finasteride, from early shedding through stabilization to visible regrowth, based on clinical evidence.

    Read more→
  • Finasteride Side Effects: What's Common, What's Rare, and What to Watch For

    A complete look at finasteride side effects, including how often each occurs in clinical trials, who's at higher risk, what's reversible, and when to see a physician.

    Read more→
  • Finasteride Before and After: What Real Results Look Like

    What finasteride results actually look like at 3, 6, and 12 months, what the clinical photo data shows, and how to set realistic expectations for your own treatment.

    Read more→
  • Finasteride vs. Dutasteride: How They Compare for Hair Loss

    An evidence-based comparison of finasteride and dutasteride for pattern hair loss, including DHT suppression, study results, side-effect profiles, and clinical use cases.

    Read more→
  • Long-Term Safety of Finasteride: What Decades of Data Show

    An evidence-based look at the long-term safety profile of finasteride for hair loss, drawing on decades of trial and post-marketing data, including prostate, cardiovascular, and persistent symptom considerations.

    Read more→
  • Topical Finasteride: A Lower-Exposure Alternative to the Oral Pill

    How topical finasteride works, what the randomized data shows about efficacy and systemic absorption compared to the oral pill, and who tends to consider it.

    Read more→
  • Finasteride for Women: What the Evidence Shows and Who's a Candidate

    An evidence-based look at finasteride for female pattern hair loss, including off-label dosing, the pregnancy contraindication, and how it fits into treatment for postmenopausal women.

    Read more→

Quick reference

Encountered a term you don’t recognize?

Our hair-loss glossary defines the medical and biological terms used across these guides.

Browse the glossary→
Curekey patient outdoors after starting treatment

Get thicker, fuller hair in 3–6 months

Prescribed by board-certified dermatologists. Delivered to your door.

Start my assessment

Takes 2 minutes · Free to start

Curekey
How it worksFAQAbout UsGuidesContact UsLogin
Start assessment